Director, Johns Hopkins Greenberg Bladder Cancer Institute
Professor of Urology The James Buchanan Brady Urological Institute
Research in Dr. McConkey’s laboratory is focused on defining the molecular mechanisms involved in bladder cancer progression and developing novel therapies for muscle-invasive disease. In current efforts he is using whole genome approaches to define the molecular heterogeneity in muscle-invasive bladder cancers and defining the molecular mechanisms that dictate sensitivity and resistance to conventional cisplatin-based combination chemotherapy, EGFR and FGFR inhibitors, and proteasome inhibitors. He is Chair for Translational Medicine in the Southwest Oncology Group’s GU Subcommittee and has been actively involved in TCGA’s Bladder Cancer Analysis Working Group.